Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

French Company To Expand U.S. Pharma Offering With CDMO Acquisition

By Novacap | June 21, 2018

Novacap, a worldwide player in pharmaceutical synthesis and advanced specialties, has signed an agreement to acquire Boston-based PCI Synthesis, a U.S. pharmaceutical contract development and manufacturing organization (CDMO).

Located in Boston’s biotech and pharmaceutical hub, PCI Synthesis offers a range of services, including process research and early stage development as well as commercial production of new chemical entities (NCEs), generic APIs, and other specialty chemical products.

The company operates an R&D facility in Devens, MA, and a manufacturing facility in Newburyport, MA, and generates some $32 million in revenue. PCI Synthesis recently closing its fifth consecutive year-to-year of double-digit growth.

That success was driven by more than 40 new customers and an expansion into new offerings such as GMP manufacturing for nutraceuticals and pharma foods, large-scale cryogenic manufacturing, large-scale chromatography, controlled substance development,  and medical-grade polymers.

The combination of the two companies will provide PCI Synthesis with additional resources to continue its development while reinforcing Novacap’s global leadership in pharmaceutical synthesis with 12 cGMP sites, two main R&D centers, and a range of services and technologies dedicated to clinical development and commercial manufacturing.

“The acquisition of PCI Synthesis perfectly fits with our strategic roadmap as it will strengthen our offering to the pharmaceutical industry and provide Novacap with a strong and innovative platform to accelerate our development in the U.S.,” said Pierre Luzeau, CEO of Novacap. “The two companies operate complementary CDMO activities and share common values.”

The closing of this acquisition remains subject to customary merger control approval.

BlackArch Partners served as the exclusive financial advisor to PCI Synthesis. Corporate law firm Sidley Austin LLP represented Novacap in the acquisition.

(Source: Novacap)

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards